Malcolm Lloyd-Smith - Aug 12, 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Aug 12, 2022
Transactions value $
-$2,281,331
Form type
4
Date filed
8/16/2022, 06:44 PM
Previous filing
Feb 9, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $775K +21.5K +114% $35.99 40.4K Aug 12, 2022 Direct
transaction NBIX Common Stock Sale -$2.28M -21.5K -53.27% $105.95 18.9K Aug 12, 2022 Direct F1, F2, F3
transaction NBIX Common Stock Options Exercise $124K +3.46K +18.29% $35.99 22.3K Aug 15, 2022 Direct
transaction NBIX Common Stock Options Exercise $145K +3.36K +15.04% $43.24 25.7K Aug 15, 2022 Direct
transaction NBIX Common Stock Options Exercise $100K +1.23K +4.77% $81.49 26.9K Aug 15, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise -$775K -21.5K -100% $35.99 0 Aug 12, 2022 Common Stock 21.5K $35.99 Direct F4
transaction NBIX Incentive Stock Option Options Exercise -$124K -3.46K -100% $35.99 0 Aug 15, 2022 Common Stock 3.46K $35.99 Direct F4
transaction NBIX Incentive Stock Option Options Exercise -$145K -3.36K -100% $43.24 0 Aug 15, 2022 Common Stock 3.36K $43.24 Direct F5
transaction NBIX Incentive Stock Option Options Exercise -$100K -1.23K -100% $81.49 0 Aug 15, 2022 Common Stock 1.23K $81.49 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.28 to $106.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Includes an aggregate of 157 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F4 Option granted February 05, 2016 and vested monthly over four years.
F5 Option granted February 06, 2017 and vested monthly over four years
F6 Option granted February 05, 2018 and vested monthly over four years